1.70

5.56% -0.10

Transcode Therapeutics Inc (RNAZ)

Overview News Price History Financials Discussions Forecast Stock Split

Transcode Therapeutics Inc stock is traded at $1.70, with a volume of 28,865. It is down -5.56% in the last 24 hours and up +1.19% over the past month. TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Previous Close:

$1.80

Open:

$1.83

24h Volume:

28,865

Relative Volume:

0.64

Market Cap:

$28.78M

Revenue:

Net Income/Loss:

$-40.36M

P/E Ratio:

-0.0349

EPS:

-48.648

Net Cash Flow:

$-21.40M

1W Performance:

-8.60%

1M Performance:

+1.19%

6M Performance:

-80.46%

1Y Performance:

-88.61%

1-Day Range:

$1.695

$1.8637

1-Week Range:

$1.63

$1.91

52-Week Range:

$1.52

$15.90

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name

Transcode Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

857-301-6857

Address

6 LIBERTY SQUARE, BOSTON

Employee

Twitter

Next Earnings Date

2026-11-13

Latest SEC Filings

RNAZ's Discussions on Twitter

Compare RNAZ vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAZ Transcode Therapeutics Inc	1.70	28.78M	0	-40.36M	-21.40M	-48.65
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Transcode Therapeutics Inc Stock (RNAZ) Latest News

Oct 01, 2026

TransCode Therapeutics Eases Near-Term Obligations Under Financing - TipRanks

Oct 01, 2026

Form 8K Transcode Therapeutics Inc For: 1 October By Investing.com - Investing.com India

Oct 01, 2026

With a waiver through October 31, TransCode Therapeutics (RNAZ) pays Yorkville. - Stock Titan

Oct 01, 2026

Sep 28, 2026

After 98 doses, TransCode (RNAZ) reports no adverse events that led patients to stop treatment. - Stock Titan

Sep 28, 2026

Sep 16, 2026

Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine

Sep 16, 2026

Sep 13, 2026

TransCode Therapeutics Share PriceRNAZ, RNS News, Articles, Quotes, & Charts (NASDAQ:RNAZ) - Proactive financial news

Sep 13, 2026

Sep 11, 2026

TransCode Therapeutics CFO Resigns, Interim Replacement Named - minichart.com.sg

Sep 11, 2026

Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria

Sep 11, 2026

Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa

Sep 11, 2026

Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com

Sep 11, 2026

Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com

Sep 11, 2026

TransCode Therapeutics Announces CFO Resignation and Interim Appointment - TipRanks

Sep 11, 2026

Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada

Sep 11, 2026

Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com UK

Sep 11, 2026

Transcode Therapeutics (RNAZ) grants CFO 185,000 options with 10-year term - Stock Titan

Sep 11, 2026

CFO exit at TransCode Therapeutics (RNAZ) comes with severance tied to future funding - Stock Titan

Sep 11, 2026

TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald - citybuzz -

Sep 11, 2026

Sep 10, 2026

TransCode Therapeutics Appoints John Tattory As Interim CFO - TradingView

Sep 10, 2026

Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 10, 2026 - marketscreener.com

Sep 10, 2026

Sep 03, 2026

Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Yahoo Finance

Sep 03, 2026

Aug 31, 2026

An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan

Aug 31, 2026

Aug 28, 2026

RNAZ Stock Price, Quote & News - Syfe

Aug 28, 2026

Aug 17, 2026

TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn

Aug 17, 2026

TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Growth Forecast - dars.gov.et

Aug 17, 2026

Aug 14, 2026

TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan

Aug 14, 2026

TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn

Aug 14, 2026

TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn

Aug 14, 2026

TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionMFI Oversold - careplusvn.com

Aug 14, 2026

TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65High Yield Stocks - dars.gov.et

Aug 14, 2026

Aug 07, 2026